4.7 Review

Application of Topical Immunotherapy in the Treatment of Alopecia Areata: A Review and Update

Journal

DRUG DESIGN DEVELOPMENT AND THERAPY
Volume 15, Issue -, Pages 1285-1298

Publisher

DOVE MEDICAL PRESS LTD
DOI: 10.2147/DDDT.S297858

Keywords

contact sensitizers; dinitrochlorobenzene; diphencyprone; diphenylcyclopropenone; hair loss; squaric acid dibutylester

Ask authors/readers for more resources

Treatment of extensive or recalcitrant alopecia areata remains a major clinical challenge, with no FDA-approved medication available yet. Topical immunotherapy, including substances like dinitrochlorobenzene, squaric acid dibutylester, and diphenylcyclopropenone, has shown efficacy in treatment, but the mechanism and clinical outcomes are still not well-understood.
Treatment of extensive or recalcitrant alopecia areata (AA) is a major clinical challenge. Even after thorough investigation of several medications, its treatment outcomes have remained unsatisfactory. While there is no US Food and Drug Administration-approved medication for AA yet, topical immunotherapy has been a well-documented treatment option. Dinitrochlorobenzene, squaric acid dibutylester, and diphenylcyclopropenone are three substances that have demonstrated efficacy in the treatment of extensive or recalcitrant AA. Despite being commonly used, the mechanism underlying topical immunotherapy is not well-elucidated and a wide range of clinical efficacies have been reported in the literature. The aim of this review was to summarize and update the pharmacology, mechanism of action, therapeutic efficacy, and tolerability of topical immunotherapy in the treatment of AA.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available